Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal
An appeal has been lodged for this appraisal. Below are the papers related to this appeal. More information on the Technology Appraisal Appeal Process can be found on the Appeals section of the NICE website.
This page was last updated: 02 July 2010